The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Open accessAbstract
HER2-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical questions, warranting the establishment of consensus to optimally treat patients with HER2-low breast tumors. Between 2022 and 2023, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process focused on HER2-low breast cancer. The consensus included a multidisciplinary panel of 32 leading experts in the management of breast cancer from 9 different countries. The aim of the consensus was to develop statements on topics that are not covered in detail in the current ESMO Clinical Practice Guideline. The main topics identified for discussion were: (i) biology of HER2-low breast cancer; (ii) pathologic diagnosis of HER2-low breast cancer; (iii) clinical management of HER2-low metastatic breast cancer and (iv) clinical trial design for HER2-low breast cancer. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. A review of the relevant scientific literature was conducted in advance. Consensus statements were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the developed statements, including findings from the expert panel discussions, expert opinion and a summary of evidence supporting each statement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Self-citationWolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,435
Self-citationLoibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Self-citationLoibl, S., & Gianni, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32417-5 · Cited by 1,116
Self-citationHER2-Low Breast Cancer: Pathological and Clinical Landscape
Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 791
Self-citationModi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Self-citationOgitani, Y., Hagihara, K., Oitate, M., Naito, H., & Agatsuma, T. (2016) · Cancer Science · doi:10.1111/cas.12966 · Cited by 751
Hurvitz, S. A., Hegg, R., Chung, W.-P., Im, S.-A., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E., Madhusudan, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02420-5 · Cited by 687
Self-citation
Cited by
Trastuzumab deruxtecan in breast cancer
Martín, M., Pandiella, A., Vargas-Castrillón, E., Díaz-Rodríguez, E., Iglesias-Hernangómez, T., Martínez Cano, C., Fernández-Cuesta, I., Winkow, E., & Perelló, M. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104355 · Cited by 103
Metadata
- Authors
- Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., Denkert, C., Diéras, V., Jacot, W., Koutras, A. K., Lebeau, A., Loibl, S., Modi, S., Mosele, M. F., Provenzano, E., Pruneri, G., Reis-Filho, J. S., Rojo, F., Salgado, R., Schmid, P., Schnitt, S. J., Tolaney, S. M., Trapani, D., Vincent-Salomon, A., Wolff, A. C., Pentheroudakis, G., André, F., & Curigliano, G.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 34
- Issue
- 8
- Pages
- 645-659
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4378978327
- Cited by
- 312
- References
- 60
- FWCI
- 32.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. https://app.cochat.ai/papers/10.1016/j.annonc.2023.05.008
- The paper
- Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., Denkert, C., Diéras, V., Jacot, W., Koutras, A. K., Lebeau, A., Loibl, S., Modi, S., Mosele, M. F., Provenzano, E., . . . Curigliano, G. (2023). ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2023.05.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
